<DOC>
	<DOCNO>NCT00575042</DOCNO>
	<brief_summary>This pilot study evaluate safety efficacy fenofibrate patient primary biliary cirrhosis incomplete response ursodeoxycholic acid .</brief_summary>
	<brief_title>Use Fenofibrate Primary Biliary Cirrhosis</brief_title>
	<detailed_description>This multicenter open label pilot study evaluate efficacy fenofibrate 20 patient PBC treat 1 year . A randomized design would feasible stage research . Two site enrol patient : University Florida , Gainesville , Mayo Clinic Rochester , first coordinate site . The total number patient start treatment exceed 20 . Our endpoint 1 ) surrogate marker disease activity -serum alkaline phosphatase immunoglobulin M ; 2 ) well validate prognostic index -Mayo risk score 3 ) NIDDK quality life questionnaire .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Established diagnosis PBC serological ( positive antimitochondrial antibody ) and/or histological evidence ( diagnostic liver biopsy ) Previous treatment UDCA 1315 mg/kg/day least 1 year Persistent elevation serum alkaline phosphatase â‰¥ 2 time upper limit normal two separate measurement Female patient childbearing age pregnancy test do within day begin trial , agree adequate contraception throughout study period Signed informed consent careful review information study detail one investigator Exclusion Criteria Hypersensitivity fenofibrate Prisoners institutionalized subject Pregnant nursing woman Anticipated need liver transplantation one year ( estimate one year survival &lt; 80 % ) determine Mayo risk score . The Mayo risk score take account patient 's age , serum bilirubin , albumin prothrombin time , well presence absence peripheral edema . Recipients liver transplantation Recurrent variceal hemorrhage , uncontrolled encephalopathy refractory ascites Coexisting liver disease , primary sclerosing cholangitis , acute chronic hepatitis , alcoholic liver disease , choledocholithiasis , autoimmune hepatitis , cholangiocarcinoma Acute chronic renal failure Known history cholecystitis intact gallbladder Current use statin , concomitant use fibrates statin would increase risk toxicity</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>PBC</keyword>
	<keyword>Primary Biliary Cirrhosis</keyword>
	<keyword>Fenofibrate</keyword>
	<keyword>Triglide</keyword>
</DOC>